Role of osteopontin in differential diagnosis of ovarian tumors

The aim of this study was to evaluate the role of the serum osteopontin (OPN) level as a biomarker for discriminating between malignant and benign ovarian tumors. Furthermore, comparisons with the diagnostic usefulness of the other tests were performed.

[1]  F. Amor,et al.  GI‐RADS reporting system for ultrasound evaluation of adnexal masses in clinical practice: a prospective multicenter study , 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[2]  S. Huffel,et al.  Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray‐scale and Doppler ultrasound findings: logistic regression models do not help , 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[3]  D. Franchi,et al.  OC21.03: Ultrasound imaging compared to a multivariate predictive algorithm combining HE4 and CA 125 (ROMA®) in the pre‐operative assessment of adnexal masses , 2011 .

[4]  J. Viola,et al.  Osteopontin-c Splicing Isoform Contributes to Ovarian Cancer Progression , 2011, Molecular Cancer Research.

[5]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[6]  R. Batchu,et al.  Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression , 2010, Archives of Gynecology and Obstetrics.

[7]  S. Huffel,et al.  Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[8]  F. Amor,et al.  Gynecologic Imaging Reporting and Data System , 2009, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[9]  Jacobus Pfisterer,et al.  Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. , 2009, Gynecologic oncology.

[10]  S. Van Huffel,et al.  Prospective Internal Validation of Mathematical Models to Predict Malignancy in Adnexal Masses: Results from the International Ovarian Tumor Analysis Study , 2009, Clinical Cancer Research.

[11]  G. Song,et al.  Osteopontin promotes ovarian cancer progression and cell survival and increases HIF‐1α expression through the PI3‐K/Akt pathway , 2008, Cancer science.

[12]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[13]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[14]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[15]  Patrick Neven,et al.  Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. , 2007, Journal of the National Cancer Institute.

[16]  L. Rodrigues,et al.  The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[17]  T. Tamaya,et al.  Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. , 2007, Journal of biomedical science.

[18]  Yinhua Yu,et al.  Potential markers that complement expression of CA125 in epithelial ovarian cancer. , 2005, Gynecologic oncology.

[19]  J. Alcázar,et al.  A new scoring system to differentiate benign from malignant adnexal masses. , 2003, American journal of obstetrics and gynecology.

[20]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[21]  L. Valentin,et al.  Comparison of ‘pattern recognition’ and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[22]  T. Bourne,et al.  Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[23]  L. Valentin,et al.  Pattern recognition of pelvic masses by gray‐scale ultrasound imaging: the contribution of Doppler ultrasound , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[24]  F. Blattner,et al.  Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection , 1989, The Journal of experimental medicine.

[25]  R. Bast,et al.  Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. , 1988, American journal of obstetrics and gynecology.

[26]  L. Shulman.  Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders , 2012 .

[27]  Yan Wu,et al.  [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. , 2010, Chinese journal of cancer.

[28]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[29]  S. Sajdak,et al.  An ultrasonographic morphological index for prediction of ovarian tumor malignancy. , 2005, European journal of gynaecological oncology.

[30]  A. Zygmunt,et al.  Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer. , 1999, European journal of gynaecological oncology.

[31]  D. Timmerman,et al.  Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[32]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.